Zobrazeno 1 - 10
of 326
pro vyhledávání: '"Moshyk, A."'
Time to an event of interest over a lifetime is a central measure of the clinical benefit of an intervention used in a health technology assessment (HTA). Within the same trial multiple end-points may also be considered. For example, overall and prog
Externí odkaz:
http://arxiv.org/abs/2401.13820
Autor:
Charmy Vyas, Andriy Moshyk, Gina Fusaro, Stergios Zacharoulis, Mir Sohail Fazeli, Nishu Gaind, Shirin Behyan, Pratik Thakkar
Publikováno v:
Melanoma Management, Vol 11, Iss 1 (2024)
Aim: This study summarized the existing evidence on the outcomes and safety of anti-PD-1s, anti-PD-L1s and anti-CTLA-4s in pediatric patients with melanoma.Materials & methods: MEDLINE® and Embase were searched from database inception to 01-12-2023.
Externí odkaz:
https://doaj.org/article/2419140d7d7542288e6b4663bedafd6a
Autor:
Wolfram Samlowski, Nicholas J. Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S. Weber
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2378-2388 (2023)
Abstract Background Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real‐world data on this regimen are limited in this setting. Methods This retrospective observational study utilized
Externí odkaz:
https://doaj.org/article/af40e545f9924238b22b08dd911e1b09
Autor:
Schadendorf, Dirk, Tawbi, Hussein, Lipson, Evan J., Stephen Hodi, F., Rutkowski, Piotr, Gogas, Helen, Lao, Christopher D., Grob, Jean-Jacques, Moshyk, Andriy, Lord-Bessen, Jennifer, Hamilton, Melissa, Guo, Shien, Shi, Ling, Keidel, Sarah, Long, Georgina V.
Publikováno v:
In European Journal of Cancer July 2023 187:164-173
Autor:
Branchoux, S., Sofeu, C.L., Gaudin, A.-F., Kurt, M., Moshyk, A., Italiano, A., Bellera, C., Rondeau, V.
Publikováno v:
In ESMO Open February 2022 7(1)
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tarhini, A.A., Toor, K., Chan, K., McDermott, D.F., Mohr, P., Larkin, J., Hodi, F.S., Lee, C.-H., Rizzo, J.I., Johnson, H., Moshyk, A., Rao, S., Kotapati, S., Atkins, M.B.
Publikováno v:
In ESMO Open April 2021 6(2)
Autor:
Stéphane Dalle, Laurent Mortier, Pippa Corrie, Michal Lotem, Ruth Board, Ana María Arance, Frank Meiss, Patrick Terheyden, Ralf Gutzmer, Brian Buysse, Kelly Oh, Jane Brokaw, T. Kim Le, Susan D. Mathias, Julie Scotto, Jennifer Lord-Bessen, Andriy Moshyk, Srividya Kotapati, Mark R. Middleton
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study (NCT01511913) in patients re
Externí odkaz:
https://doaj.org/article/99594f7922fa4fff9fddfd1d9103f9ac
Autor:
Kabirraaj Toor, Mark R. Middleton, Keith Chan, Adenike Amadi, Andriy Moshyk, Srividya Kotapati
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Immune checkpoint inhibitors and targeted therapies are approved for adjuvant treatment of patients with resected melanoma; however, they have not been compared in randomized controlled trials (RCTs). We compared the efficacy and
Externí odkaz:
https://doaj.org/article/9229b82e8dee4f2dbaac9757d91d7c68
Autor:
Victoria Federico Paly, Murat Kurt, Lirong Zhang, Marcus O. Butler, Olivier Michielin, Adenike Amadi, Emma Hernlund, Helen M. Johnson, Srividya Kotapati, Andriy Moshyk, John Borrill
Publikováno v:
MDM Policy & Practice, Vol 7 (2022)
Background Survival heterogeneity and limited trial follow-up present challenges for estimating lifetime benefits of oncology therapies. This study used CheckMate 067 (NCT01844505) extended follow-up data to assess the predictive accuracy of standard
Externí odkaz:
https://doaj.org/article/f0c69c404a25446e92904de57323a318